Intarcia Therapeutics Announces Upcoming Presentation at 35th Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 6, 2017 /PRNewswire/ -- Intarcia Therapeutics, Inc., today announced that Chairman, President and CEO Kurt Graves will present a Company overview at the J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco:

• 8:00am Pacific Time, Monday, January 9^th: Elizabethan Meeting Room (C & D)

About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment and prevention outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. Delivering medicines just once- or twice yearly to prevent and/or chronically treat diseases holds potential to improve outcomes by improving effectiveness over time and by addressing real-world unmet needs around poor patient adherence and persistence rates that are high in the majority of chronic diseases. Intarcia is investigating multiple therapies, including combination therapies, for chronic diseases leveraging the convergence of novel medicines and the proprietary Medici Drug Delivery System™. Intarcia is developing a strong pipeline in important therapeutic areas, including: diabetes, obesity, autoimmune diseases, HIV, and other serious disorders.

For more information on the Company, please visit www.intarcia.com.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc.

Follow us on Twitter @intarcia.

SOURCE Intarcia Therapeutics, Inc.

Related Links

http://www.intarcia.com